Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SAIRAH AHMED and RICHARD E CHAMPLIN.
SAIRAH AHMED
Connection Strength
4.457
RICHARD E CHAMPLIN
  1. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024 May; 59(5):699-704.
    View in: PubMed
    Score: 0.236
  2. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 04; 99(4):562-569.
    View in: PubMed
    Score: 0.235
  3. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol. 2024 01; 204(1):e11-e16.
    View in: PubMed
    Score: 0.230
  4. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44.
    View in: PubMed
    Score: 0.213
  5. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303.
    View in: PubMed
    Score: 0.209
  6. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.
    View in: PubMed
    Score: 0.198
  7. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5.
    View in: PubMed
    Score: 0.192
  8. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.
    View in: PubMed
    Score: 0.191
  9. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
    View in: PubMed
    Score: 0.151
  10. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017 10 19; 130(16):1857-1868.
    View in: PubMed
    Score: 0.151
  11. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12.
    View in: PubMed
    Score: 0.126
  12. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1618-25.
    View in: PubMed
    Score: 0.121
  13. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood. 2024 Oct 23.
    View in: PubMed
    Score: 0.062
  14. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe. 2024 Sep 11; 32(9):1621-1636.e6.
    View in: PubMed
    Score: 0.061
  15. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):e819-e826.
    View in: PubMed
    Score: 0.061
  16. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther. 2023 Nov; 29(11):690-694.
    View in: PubMed
    Score: 0.057
  17. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther. 2024 Feb; 30(2):205.e1-205.e12.
    View in: PubMed
    Score: 0.057
  18. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023 04; 29(4):906-916.
    View in: PubMed
    Score: 0.055
  19. Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq. 2023 Jan 31.
    View in: PubMed
    Score: 0.055
  20. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.
    View in: PubMed
    Score: 0.054
  21. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med. 2022 11 15; 3(11):100720.
    View in: PubMed
    Score: 0.054
  22. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022 09 29; 185(20):3705-3719.e14.
    View in: PubMed
    Score: 0.054
  23. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393.
    View in: PubMed
    Score: 0.053
  24. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplant Cell Ther. 2022 10; 28(10):681-693.
    View in: PubMed
    Score: 0.053
  25. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9.
    View in: PubMed
    Score: 0.052
  26. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Adv. 2022 04 12; 6(7):2267-2274.
    View in: PubMed
    Score: 0.052
  27. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022 04 01; 107(4):899-908.
    View in: PubMed
    Score: 0.052
  28. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant. 2022 01; 57(1):51-56.
    View in: PubMed
    Score: 0.050
  29. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.
    View in: PubMed
    Score: 0.047
  30. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.
    View in: PubMed
    Score: 0.046
  31. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306.
    View in: PubMed
    Score: 0.045
  32. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020 05 15; 126(10):2183-2192.
    View in: PubMed
    Score: 0.045
  33. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.
    View in: PubMed
    Score: 0.044
  34. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787.
    View in: PubMed
    Score: 0.043
  35. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma. 2019 12; 60(14):3536-3543.
    View in: PubMed
    Score: 0.043
  36. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
    View in: PubMed
    Score: 0.042
  37. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018 Nov 02; 9(86):35611-35622.
    View in: PubMed
    Score: 0.041
  38. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.
    View in: PubMed
    Score: 0.041
  39. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5.
    View in: PubMed
    Score: 0.041
  40. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2018 10 11; 379(15):1443-1451.
    View in: PubMed
    Score: 0.041
  41. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609.
    View in: PubMed
    Score: 0.039
  42. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
    View in: PubMed
    Score: 0.039
  43. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 05; 24(5):1079-1087.
    View in: PubMed
    Score: 0.039
  44. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. 2017 Dec; 99(6):532-535.
    View in: PubMed
    Score: 0.038
  45. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292.
    View in: PubMed
    Score: 0.037
  46. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 06 01; 129(22):3031-3033.
    View in: PubMed
    Score: 0.037
  47. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer. 2017 Jul 15; 123(14):2661-2670.
    View in: PubMed
    Score: 0.037
  48. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.037
  49. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion. 2017 04; 57(4):1052-1057.
    View in: PubMed
    Score: 0.036
  50. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2017 Feb; 19(1).
    View in: PubMed
    Score: 0.036
  51. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292.
    View in: PubMed
    Score: 0.036
  52. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017 01; 102(1):110-117.
    View in: PubMed
    Score: 0.035
  53. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
    View in: PubMed
    Score: 0.035
  54. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8.
    View in: PubMed
    Score: 0.034
  55. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016 05; 173(3):444-55.
    View in: PubMed
    Score: 0.034
  56. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5.
    View in: PubMed
    Score: 0.034
  57. Outcomes of Haploidentical Stem Cell Transplantation for?Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. 2016 Mar; 22(3):493-8.
    View in: PubMed
    Score: 0.033
  58. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.
    View in: PubMed
    Score: 0.033
  59. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20.
    View in: PubMed
    Score: 0.032
  60. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):472-6.
    View in: PubMed
    Score: 0.032
  61. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
    View in: PubMed
    Score: 0.032
  62. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1975-81.
    View in: PubMed
    Score: 0.031
  63. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1227-32.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.